Roche-sponsored satellite symposium at EULAR 2019
Putting New Evidence into Clinical Practice
in GCA and RA–Together We Dare
held on Thursday 13 June 2019
This year’s Roche EULAR symposium entitled Putting New Evidence into Clinical Practice in GCA
and RA–Together We Dare, addressed the practical applications of new clinical evidence in giant cell
arteritis (GCA) and rheumatoid arthritis (RA) to improve patient care. With new clinical evidence, the symposium
presenters emphasized how rheumatologists are now better equipped than ever before to manage these conditions.
In his presentation, New Insights into the Treatment of GCA, Dr John Stone
highlighted that since GCA is a chronic, life-altering condition, early recognition
and diagnosis is paramount. Using information from his own clinic and the
latest GiACTA trial data, Dr Stone explored new therapeutic strategies to enable
sustained disease control, while tapering glucocorticoids, thereby leading to
improved patient outcomes.
In his presentation, Strengthening the Treatment Paradigm in RA,
Dr Frank Buttgereit stressed the importance of shared decision-making to
improve the treatment of RA and illustrated this point with respect to the use
of glucocorticoids and their limitations. Using data from the SEMIRA trial,
he explained how rheumatologists can maintain patients in low disease
activity and can taper their glucocorticoids.
In a panel discussion, Debating the evidence in RA and GCA, attendees
submitted questions to the presenters. Discussions drew upon the
parallels and differences between GCA and RA and detailed why and
how new data should inspire confidence among rheumatologists about
setting more ambitious goals for treating their patients to enable better
disease control with less treatment burden.
Roche Satellite Symposium Video
Following the Roche symposium, Dr Stone provided a summary of the
event and its outcomes